Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials

Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials

Background: We aimed to investigate the potential beneficial effect of immunomodulation therapy on the thromboembolic risk in hospitalized COVID-19 patients. Methods: We searched PubMed and Scopus for randomized trials reporting the outcomes of venous thromboembolism (VTE), ischemic stroke or system...

Full description

Bibliographic Details
Main Authors: Dimitrios Sagris, Matilda Florentin, Panagiotis Tasoudis, Eleni Korompoki, Nikolaos Gatselis, Evangelos J. Giamarellos-Bourboulis, Haralampos Milionis, James Douketis, Alex C. Spyropoulos, George Dalekos, George Ntaios
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Journal of Clinical Medicine
Subjects:
COVID-19
thromboembolism
tocilizumab
anakinra
hydroxycholoroquine
immunomodulation
Online Access:https://www.mdpi.com/2077-0383/10/22/5366

Internet

https://www.mdpi.com/2077-0383/10/22/5366

Similar Items